Chronic Kidney Disease Stage VAR-MHDNCT07412548
Autogenic Relaxation and Murottal Therapy in Hemodialysis Patients
A study testing Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy and listening to dangdut music in people with Chronic Kidney Disease Stage V and End-Stage Renal Disease, run by Universitas Muhammadiyah Surakarta at 1 site in Indonesia.
Trial summary
This quasi-experimental study aims to evaluate the effect of combined autogenic relaxation and Surah Ar-Rahman murottal therapy on anxiety, sleep quality, and hemodynamic parameters in hemodialysis patients. A pretest-posttest control group design will be used involving 76 participants undergoing routine hemodialysis. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Chronic Kidney Disease Stage V, End-Stage Renal Disease, Hemodialysis
- What is being tested?
- Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy and listening to dangdut music
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 76 participants
- Where
- 1 siteIndonesia
- Study dates
- 1 Mar 2026to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients diagnosed with stage V chronic kidney disease.
- Undergoing scheduled hemodialysis at least twice a week for 6 weeks.
- Outpatients and aged 18-65 years.
- Muslim.
- Cooperative and able to communicate verbally.
- Willing to be a respondent by signing an informed consent form.
Who cannot join
- Having a severe heart condition or an unstable critical condition.
- Having a severe psychiatric disorder (schizophrenia, major depression).
- Having a cognitive, hearing, or speech disorder that impedes communication.
- Taking antidepressants, anxiolytics, or neuroleptics that may affect psychological measurement results.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Indonesia1 site
Indriati Hospital
Sukoharjo, Central Java, 57552
Rina Hastuti, dr, +6285647040989, dr_rinahastuti@yahoo.com
Ai Hendayani, S.Kep.,Ns, +62895326540109, hendayani.ai.90@gmail.com
About this study
Official title: The Effectiveness of Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy on Anxiety, Sleep Quality, and Hemodynamic Parameters in Hemodialysis Patients
This quasi-experimental study aims to evaluate the effect of combined autogenic relaxation and Surah Ar-Rahman murottal therapy on anxiety, sleep quality, and hemodynamic parameters in hemodialysis patients. A pretest-posttest control group design will be used involving 76 participants undergoing routine hemodialysis. Participants will be assigned to an intervention group receiving structured autogenic relaxation followed by murottal therapy and a control group receiving standard care with music listening. Anxiety, sleep quality, and hemodynamic parameters will be measured at baseline and after a 6-week intervention period. The findings are expected to support the use of non-pharmacological and spiritual-based interventions in improving psychological and physiological outcomes in hemodialysis patients.
Read the detailed description
This study applies a quasi-experimental pretest-posttest control group design. The intervention group receives structured autogenic relaxation followed by Surah Ar-Rahman murottal therapy for 10-15 minutes per session, twice weekly for six weeks. The control group receives standard hemodialysis care with music listening. Anxiety, sleep quality, and hemodynamic parameters are assessed before and after the intervention.
- Being tested
- Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy, listening to dangdut music
- Keywords
- Autogenic Relaxation, Murottal Therapy, Anxiety, Sleep Quality, Hemodynamics
- Medical subject headings
- Kidney Failure, Chronic, Anxiety Disorders, Sleep Initiation and Maintenance Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Autogenic Relaxation and Surah Ar-Rahman Murottal TherapyBehavioural
A structured non-pharmacological intervention consisting of autogenic relaxation techniques including breathing regulation, muscle relaxation, and self-suggestion, followed by listening to Surah Ar-Rahman murottal recitation using earphones. Each session lasts 10-15 minutes and is conducted twice weekly for six weeks during routine hemodialysis.
listening to dangdut musicOther
listening to dangdut music for 10 to 15 minutes within 6 weeks
| Study group | Role | What they receive |
|---|---|---|
| Autogenic Relaxation and Murottal Therapy Surah Ar-Rahman | Experimental | Participants in this group receive structured autogenic relaxation followed by Surah Ar-Rahman murottal therapy during hemodialysis sessions. The intervention is administered twice weekly for six weeks, with each session lasting 10-15 minutes. The procedure is conducted by trained nurses under researcher supervision in a quiet and comfortable environment. Receives: Behavioral: Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy |
| Standard Care | Active comparator | listening to dangdut music for 10 to 15 minutes within 6 weeks Receives: Other: listening to dangdut music |
What is being measured
The primary outcome is the main question the study is designed to answer.
Anxiety
Change in anxiety level measured using the Zung Self-Rating Anxiety Scale (ZSAS; range 20-80), where higher scores indicate greater anxiety, from baseline to after completion of the 6-week intervention.
Measured: Baseline and after completion of the 6-week intervention
Sleep Quality
Change in sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI; range 0-21), where higher scores indicate poorer sleep quality, from baseline to after completion of the 6-week intervention.
Measured: Baseline and after completion of the 6-week intervention.
Blood Presure
Change in systolic blood pressure (mmHg), measured using a calibrated digital sphygmomanometer, from baseline to after completion of the 6-week intervention.
Measured: Baseline and after completion of the 6-week intervention
Heart Rate
Change in heart rate (beats per minute, bpm), measured using a digital bedside patient monitor, from baseline to after completion of the 6-week intervention.
Measured: Baseline and after completion of the 6-week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start1 Mar 2026 (estimated)
- Primary completion31 May 2026 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney Disease Stage VStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- This study uses a parallel assignment quasi-experimental pretest-posttest control group design. Participants are assigned into two groups: an intervention group receiving structured autogenic relaxation combined with Surah Ar-Rahman murottal therapy, and a control group receiving standard hemodialysis care with music listening. Both groups undergo baseline (pretest) and post-intervention (posttest) assessments of anxiety, sleep quality, and hemodynamic parameters. The intervention is administered twice weekly for six weeks.
- Masking
- None (open label)
- Enrolment
- 76 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universitas Muhammadiyah Surakarta
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dyan Kurniasari, Universitas Muhammadiyah Surakarta
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07412548
- Sponsor's protocol ID
- UMS-HD-ARMR-2026-01
- Acronym
- AR-MHD
- Status last verified
- Feb 2026
- First submitted
- 27 Jan 2026
- Last updated
- 17 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effectiveness of Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy on Anxiety, Sleep Quality, and Hemodynamic Parameters in Hemodialysis Patients
- ClinicalTrials.gov ID
- NCT07412548
- Acronym / sponsor ID
- AR-MHD / UMS-HD-ARMR-2026-01
- Keywords
- Autogenic Relaxation, Murottal Therapy, Anxiety, Sleep Quality, Hemodynamics
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 76 participants (estimated)
- Lead sponsor
- Universitas Muhammadiyah SurakartaUniversity, hospital or other
- Study start
- 1 Mar 2026 (estimated)
- Primary completion
- 31 May 2026 (estimated)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 17 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This quasi-experimental study aims to evaluate the effect of combined autogenic relaxation and Surah Ar-Rahman murottal therapy on anxiety, sleep quality, and hemodynamic parameters in hemodialysis patients. A pretest-posttest control group design will be used involving 76 participants undergoing routine hemodialysis. Participants will be assigned to an intervention group receiving structured autogenic relaxation followed by murottal therapy and a control group receiving standard care with music listening. Anxiety, sleep quality, and hemodynamic parameters will be measured at baseline and after a 6-week intervention period. The findings are expected to support the use of non-pharmacological and spiritual-based interventions in improving psychological and physiological outcomes in hemodialysis patients.
Detailed description
This study applies a quasi-experimental pretest-posttest control group design. The intervention group receives structured autogenic relaxation followed by Surah Ar-Rahman murottal therapy for 10-15 minutes per session, twice weekly for six weeks. The control group receives standard hemodialysis care with music listening. Anxiety, sleep quality, and hemodynamic parameters are assessed before and after the intervention.
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study uses a parallel assignment quasi-experimental pretest-posttest control group design. Participants are assigned into two groups: an intervention group receiving structured autogenic relaxation combined with Surah Ar-Rahman murottal therapy, and a control group receiving standard hemodialysis care with music listening. Both groups undergo baseline (pretest) and post-intervention (posttest) assessments of anxiety, sleep quality, and hemodynamic parameters. The intervention is administered twice weekly for six weeks.
| Arm | Type | Receives |
|---|---|---|
| Autogenic Relaxation and Murottal Therapy Surah Ar-Rahman | Experimental | Behavioral: Autogenic Relaxation and Surah Ar-Rahman Murottal TherapyParticipants in this group receive structured autogenic relaxation followed by Surah Ar-Rahman murottal therapy during hemodialysis sessions. The intervention is administered twice weekly for six weeks, with each session lasting 10-15 minutes. The procedure is conducted by trained nurses under researcher supervision in a quiet and comfortable environment. |
| Standard Care | Active comparator | Other: listening to dangdut musiclistening to dangdut music for 10 to 15 minutes within 6 weeks |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patients diagnosed with stage V chronic kidney disease.
- Undergoing scheduled hemodialysis at least twice a week for 6 weeks.
- Outpatients and aged 18-65 years.
- Muslim.
- Cooperative and able to communicate verbally.
Key exclusion criteria (4 listed)
- Having a severe heart condition or an unstable critical condition.
- Having a severe psychiatric disorder (schizophrenia, major depression).
- Having a cognitive, hearing, or speech disorder that impedes communication.
- Taking antidepressants, anxiolytics, or neuroleptics that may affect psychological measurement results.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Autogenic Relaxation and Surah Ar-Rahman Murottal TherapyA structured non-pharmacological intervention consisting of autogenic relaxation techniques including breathing regulation, muscle relaxation, and self-suggestion, followed by listening to Surah Ar-Rahman murottal recitation using earphones. Each session lasts 10-15 minutes and is conducted twice weekly for six weeks during routine hemodialysis. | Behavioural | Autogenic Relaxation and Murottal Therapy Surah Ar-Rahman |
| listening to dangdut musiclistening to dangdut music for 10 to 15 minutes within 6 weeks | Other | Standard Care |
Primary outcome
Anxiety
Time frame: Baseline and after completion of the 6-week intervention
Change in anxiety level measured using the Zung Self-Rating Anxiety Scale (ZSAS; range 20-80), where higher scores indicate greater anxiety, from baseline to after completion of the 6-week intervention.
Sleep Quality
Time frame: Baseline and after completion of the 6-week intervention.
Change in sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI; range 0-21), where higher scores indicate poorer sleep quality, from baseline to after completion of the 6-week intervention.
Blood Presure
Time frame: Baseline and after completion of the 6-week intervention
Change in systolic blood pressure (mmHg), measured using a calibrated digital sphygmomanometer, from baseline to after completion of the 6-week intervention.
Heart Rate
Time frame: Baseline and after completion of the 6-week intervention
Change in heart rate (beats per minute, bpm), measured using a digital bedside patient monitor, from baseline to after completion of the 6-week intervention.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2026.
- Anxiety reduction in chronic kidney disease (CKD) patients undergoing hemodialysis through acupressure and Quranic recitation interventionsLink provided by the sponsor.
- Penerapan Mindfulness Terhadap Kecemasan Pada Pasien Penyakit Ginjal Kronik (PGK) Yang Menjalankan Hemodialisa Di RSUD Kota Bogor.Link provided by the sponsor.
- Assessment of prevalence of anxiety in adult population and development of anxiety scaleLink provided by the sponsor.
- Prevalence of poor sleep quality and associated factors among hypertensive patientsLink provided by the sponsor.
- A comparison of ultra-brief cognitive defusion and positive self-affirmationLink provided by the sponsor.
- Implementasi Hamilton Anxiety Rating Scale. JICON, 10(1), 55-64Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Chronic Kidney Disease Stage V
Not yet recruitingObservational study
Hyperparathyroidism and Dialysis Adequacy in Hemodialysis Patients
Hyperparathyroidism, Secondary, Kidney Failure, Chronic
Not yet recruiting
Feasibility of the COMFORT (COmplex Symptom Management Intervention FOR adulTs With Advanced Kidney Disease) Intervention for Adults With Advanced Kidney Disease and Their Informal Caregivers
Chronic Kidney Disease (Stages 4 and 5)
Recruiting
CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
Chronic Kidney Disease Stage 5, End Stage Renal Disease
Recruiting
A Communication-Priming Intervention to Improve Shared Decision-Making Between Older Adults With Advanced CKD and Clinicians
Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5
Recruiting
Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)
Chronic Kidney Disease (CKD) Stage 5, Kidney Dysfunction Requiring Dialysis (KDRD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy and listening to dangdut music in people with Chronic Kidney Disease Stage V and End-Stage Renal Disease, run by Universitas Muhammadiyah Surakarta at 1 site in Indonesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dyan Kurniasari, S.Kep.,Ns (+628122593391, j218240018@student.ums.ac.id), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anxiety (time frame: Baseline and after completion of the 6-week intervention). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.